Rise Health & Wellness Peptides

1. IGF-1 Receptor Binding: Binds to the IGF-1 receptor (IGF1R) on muscle, bone, nerve, and other cells, activating intracellular signaling cascades.

PI3K–Akt Pathway Activation: Stimulates cell survival, protein synthesis, and growth.

MAPK/ERK Pathway Activation: Regulates cellular proliferation and differentiation.

2. Enhanced Cell Growth and Repair: Promotes hypertrophy (cell enlargement) and hyperplasia (new cell formation), accelerating tissue regeneration.

3. Inhibition of Apoptosis: Reduces programmed cell death in stressed or damaged tissues, supporting recovery and adaptation.

4. Insulin-Like Effects: Increases glucose uptake and enhances nutrient partitioning toward muscle tissue.

5. Reduced IGF Binding Protein Interaction: The LR3 modification decreases affinity for IGF Binding Proteins (IGFBPs), increasing bioavailability and biological activity.

1. IGF-1 and Muscle Growth

• Study focus: Muscle hypertrophy and regeneration
• Key findings: Activated satellite cells and enhanced repair in aged and damaged muscle tissue
• PMID: 12086871

2. IGF-1 in Aging and Sarcopenia

• Study focus: IGF-1 levels and age-related muscle decline
• Key findings: Low IGF-1 associated with reduced muscle mass; therapeutic potential in preventing sarcopenia
• PMID: 15472188

3. IGF-1 and Neuroprotection

• Study focus: Neurodegeneration and cognitive function
• Key findings: Improved neuronal survival and enhanced brain plasticity in animal models
• PMID: 16111792

4. IGF-1 and Bone Density

• Study focus: Osteoblast activity and bone mineral density
• Key findings: Supported bone formation and density improvements
• PMID: 12820789

5. IGF-1 in Metabolic Regulation

• Study focus: Glucose uptake and insulin sensitivity
• Key findings: Increased glucose uptake and improved metabolic markers
• PMID: 14578287

6. IGF-1 LR3 Specific Research

• Study focus: Extended half-life and reduced IGFBP binding
• Key findings: Demonstrated enhanced anabolic activity in experimental models
• Summary Article: “IGF-1 and its analogs: potential for treating muscle wasting disorders”
• PMID: 15959526